Researchers at the University of Oulu have created a new method to analyze how individual patient tumor samples respond to drugs.This new pipeline is a major step towardpersonalized medicine because it addresses the difficulty in identifying the right drug, or combination of drugs, for each patient.
This pipeline uses live-cell barcoding to screen 96 drug treatments at single-cell resolution simultaneously.In a study focusing on high-grade serous ovarian cancer (HGSOC), the pipeline revealed the complex transcriptional landscape of tumors treated with 45 different drugs, representing 13 classes of mechanism of action.
Traditional cell line models often oversimplify the biology of real tumors, making it challenging to predict how a patient will respond to therapy.Working with primary patient samples not only improves the accuracy of these predictions but also opens the door to building a large-scale, data-driven “omics” database of drug responses.Researchers are hopeful that a comprehensive drug response database will significantly enhance the ability to match patients with the therapies most likely to be effective, ultimately improving outcomes in personalized cancer treatment.
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- JMKX007129: A Next‑Generation AR‑NTD Inhibitor for Overcoming Resistance in mCRPC March 20, 2026
- AUTOTAC Degraders ATB‑238 and ATB‑239 Target AR and AR‑v7 in Advanced Prostate Cancer March 20, 2026
- ²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer March 20, 2026
- HLX3902: A Trispecific T‑Cell Engager Rewiring the Immune Desert in Prostate Cancer March 19, 2026
